Clinics in Dermatology
Volume 25, Issue 3 , Pages 334-340 , May 2007

Evidence-based therapy for cutaneous sarcoidosis

References 

  1. Baughman RP, Selroos O. Evidence-based approach to the treatment of sarcoidosis. In:  Gibson PG,  Abramson M,  Wood-Baker R,  Volmick J,  Hensley M,  Costabel U editor. Evidence-based respiratory medicine. Malden: Blackwell Publishing Ltd; 2005;p. 491–508
  2. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–173
  3. Siltzbach LE. Effects of cortisone in sarcoidosis: a study of thirteen patients. Am J Med. 1952;12:139–160
  4. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol. 1992;72:69–71
  5. Fisher AA. Sarcoid-like periocular dermatitis due to strong topical corticosteroids: prompt response to treatment with tetracycline. Cutis. 1987;40:95–96
  6. Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol. 1976;94(Suppl 12):51–58
  7. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005;CD001114:
  8. Mana J, Gomez VC, Montero A, et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med. 1999;107:240–245
  9. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;208:525–533
  10. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99:307–315
  11. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis. 1998;15:52–58
  12. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111:623–631
  13. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:198–204
  14. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The sarcoidosis health questionnaire. A new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168:323–329
  15. Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci. 2003;325:1–6
  16. Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis. 1988;5:93–98
  17. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax. 1998;53:425–429
  18. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;163:2619–2624
  19. Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax. 1995;50:555–559
  20. Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur J Respir. 1993;6:116–119
  21. Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax. 1992;47:932–936
  22. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997;61:382–385
  23. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int. 1991;49:71–76
  24. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum. 1987;16:206–221
  25. Hirsch JG. Experimental treatment with chloroquine. Am Rev Respir Dis. 1961;84:52–58
  26. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand. 1964;425:302S–308S
  27. Morse SI, Cohn ZA, Hirsch JG, Shaedler RW. The treatment of sarcoidosis with chloroquine. Am J Med. 1961;30:779–784
  28. Paramothayan S, Lasserson T, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2003;CD003536:
  29. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990;23:487–489
  30. Zic J, Horowitz D, Arzubiaga C, King L. Treatment of cutaneous sarcoidosis with chloroquine: review of the literature. Arch Dermatol. 1991;127:1034–1040
  31. Liedtka JE. Intralesional chloroquine for the treatment of cutaneous sarcoidosis. Int J Dermatol. 1996;35:682–683
  32. Bartel PR, Roux P, Robinson E, Anderson IF. Visual function and long-term chloroquine treatment. South African J Med. 1994;84:32–34
  33. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 1999;140:3–7
  34. Mazzuca SA, Yung R, Brandt KD, Yee RD, Katz BP. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol. 1994;21:59–63
  35. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol. 1997;36:599–601
  36. Baughman RP, Winget DB, Lower EE. Prospective, randomized, double blind trial of methotrexate as a steroid sparing agent for sarcoidosis: analysis of first 25 patients. Am J Respir Crit Care Med. 1997;155:A944
  37. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–851
  38. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 2002;8:470–476
  39. Dev S, McCallum RM, Jaffe GJ. Methotrexate for sarcoid-associated panuveitis. Ophthalmology. 1999;106:111–118
  40. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139
  41. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med. 1997;157:1864–1868
  42. Rajendran R, Theertham M, Salgia R, Muthuswamy P. Methotrexate in the treatment of cutaneous sarcoidosis. Sarcoidosis. 1994;11:S335–S338
  43. Veien NK. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol. 1986;4:75–87
  44. Gedalia A, Molina JF, Ellis GS, Galen W, Moore C, Espinoza LR. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997;130:25–29
  45. Henderson CA, Ilchyshyn A, Curry AR. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med. 1994;87:632–633
  46. Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991;24:451–454
  47. Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol. 1977;97:213–216
  48. Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis. 1988;5:51–55
  49. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med. 1994;121:833–841
  50. Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis & Rheumatism. 1995;38:1115–1119
  51. Kremer JM, Alarcon GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316–328
  52. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis. 1996;55:273–275
  53. Roenigk HH, Auerbach R, Mailbach HI, Weinstein GD. Methotrexate guidelines revised. J Am Acad Dermatol. 1982;6:145–155
  54. Baughman RP, Weber FL, Bejarano PB, Koehler A, Lower EE. Methotrexate for chronic sarcoidosis: hepatotoxicity assessed by liver biopsy. Am J Respir Crit Care Med. 1999;159:A342
  55. Zisman DA, McCune WJ, Tino G, Lynch JP. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:243–252
  56. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47:628–633
  57. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis. 1997;14:121–130
  58. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–48
  59. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254–273
  60. Perri AJ, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J. 2003;9:5
  61. Baughman RP, Lower EE. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol. 2004;5:385–394
  62. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227–232
  63. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995;32:866–869
  64. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol. 1998;39:835–838
  65. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004;50:235–241
  66. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102:225–236
  67. Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol. 1998;134:1045–1046
  68. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1:194–205
  69. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137:69–73
  70. Eishi Y, Suga M, Ishige I, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 2002;40:198–204
  71. Kalish RS, Koujak S. Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Clin Immunol. 2004;113:270–277
  72. Kloppenburg M, Verweij CL, Miltenburg AM, et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol. 1995;102:635–641
  73. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133:1224–1230
  74. Breuer K, Gutzmer R, Volker B, Kapp A, Werfel T. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol. 2005;152:1290–1295
  75. Nowack U, Gambichler T, Hanefeld C, Kastner U, Altmeyer P. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol. 2002;2:15
  76. Frizzell B, Stith M, Jenrette J. Management of treatment-resistant cutaneous sarcoidosis with radiation. Am J Clin Oncol. 2002;25:573–575
  77. Grema H, Greve B, Raulin C. Scar sarcoidosis-treatment with the Q-switched ruby laser. Lasers Surg Med. 2002;30:398–400
  78. Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol. 2002;147:154–156
  79. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70–74
  80. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064–1071
  81. Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2003;48:290–293
  82. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol. 2004;150:146–149
  83. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2005;1–2
  84. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124:177–185
  85. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman AH. Etanercept for refractory sarcoidosis: results of a double blind randomized trial. Chest. 2005;128:1062–1067
  86. Baughman RP, Drent M, Kavuru MS, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802

PII: S0738-081X(07)00065-X

doi: 10.1016/j.clindermatol.2007.03.011

Clinics in Dermatology
Volume 25, Issue 3 , Pages 334-340 , May 2007

Article Tools

* Image Usage & Resolution